+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The role of the protocol biopsies in renal allograft recipients



The role of the protocol biopsies in renal allograft recipients



Transplantation Proceedings 35(6): 2179-2181



Subclinical rejection and long-term cyclosporine nephrotoxicity are well-known risk factors of chronic allograft nephropathy. In a prospective study 32 low-risk patients were randomized to either a reduced CsA dose (5 mg/kg/d) and daclizumab (group A, n = 16) for 7 months posttransplant with subsequent CsA tapering/withdrawal, or to a normal CsA dose (10 mg/kg/day) without daclizumab (group B, n = 16). Both groups received MMF and prednisone. Protocol biopsies were obtained at engraftment and 3 and 12 months after Tx. The number of rejection episodes was the primary endpoint. The secondary endpoints were: renal function, histological parameters related to CsA, and serum levels of TGF-beta and PDGF-BB. A low incidence of clinically suspected rejection episodes was observed (19% in group A and 12.4% in group B; P = NS). Although protocol biopsies showed 12 subclinical rejection episodes (six in group A, six in group B), serum creatinine levels were not different between the examined groups at 3 months. However, at 12 months, there was a statistically improved mean creatinine level in group A patients (1.2 mg/dL +/- 0.5 in group A vs 1.54 mg/dL in group B; P <.05). Chronic histopathologic changes were significant for biopsies at 3 and 12 months in both groups compared to the baseline findings for protocol biopsies (with no differences between groups, or between 3 and 12 months in both groups). Serum TGF-beta and PDGF-BB did not differ between the groups. Protocol biopsies may be useful to monitor safety and efficiency of new immunosuppressive protocols. Immunosuppressive regimens with low CsA doses followed by the drug's complete withdrawal seem to be efficient and safe in low-risk kidney allograft recipients.

(PDF emailed within 0-6 h: $19.90)

Accession: 012680063

Download citation: RISBibTeXText

PMID: 14529881

DOI: 10.1016/s0041-1345(03)00807-8


Related references

Protocol biopsies in the management of renal allograft recipients. Current Opinion in Nephrology and Hypertension 9(6): 615-619, 2000

Protocol biopsies should be standard of care for pediatric renal allograft recipients!. Pediatric Transplantation 10(7): 760-765, 2006

Use of ultrasound and cystoscopically guided pancreatic allograft biopsies and transabdominal renal allograft biopsies: safety and efficacy in kidney-pancreas transplant recipients. Journal of Urology 153(2): 316-321, 1995

Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplantation Proceedings 28(2): 998-999, 1996

Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 69(9): 1849-1855, 2000

Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrology, Dialysis, Transplantation 27(1): 435-443, 2012

Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 65(11): 1506-1509, 1998

Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients. Transplantation Proceedings 37(2): 773-775, 2005

Can pre-implantation biopsies predict renal allograft function in pediatric renal transplant recipients?. Saudi Medical Journal 36(11): 1299-1304, 2016

Protocol allograft biopsies and renal functional reserve. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 908A, September, 2001

C4d deposition in early renal allograft protocol biopsies. Transplantation 78(3): 398-403, 2004

The impact of CMV infections and acute rejection episodes on the development of vascular changes in 6 months protocol biopsies of cadaveric kidney allograft recipients. Nephrology Dialysis Transplantation 17(Abstracts Supplement 1): 313, 2002

Transplant vasculopathy in early protocol renal allograft biopsies. Transplantation Proceedings 31(6): 2219-2220, 1999

Importance of late allograft biopsies in pediatric renal transplant recipients. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 709A, Sept, 1998